Flu, or influenza, vaccines are designed to cause antibodies against the virus to develop in your body about two weeks after you receive the shot, according to the CDC. Antibodies are proteins created by your immune system that provide protection against infection with the viruses that are used to make vaccine, which varies from year to year based on what research suggests will be the most common during the winter season, the agency says Continue reading →

The anti-inflammatory medication VX-765, which is delivered through the nose (intranasal), was found to limit disease progression in a preclinical model of multiple sclerosis (MS) by blocking a protein called caspase-1. The medication helped prevent damage to brain cells in mice. Researchers from the University of Alberta, in Canada, showed that injecting VX-765 a known caspase-1 inhibitor into the noses of the mice reduced signs of nerve cell degeneration seen in response to the proteins activation. Continue reading →

This is great news for people with MS in England and Wales. Mayzent (siponimod) is a needed weapon in the MS battle. It is approved for use in active cases of secondary progressive MS (SPMS), while most other disease-modifying therapies (DMTs) arent Continue reading →

From the National MS Society If you or someone you know is contemplating suicide, help is out there. Reach out to the National Suicide Prevention Lifeline at 1-800-273-8255. Continue reading →

Eli Lilly has reached an agreement to acquire Disarm Therapeutics, a biotechnology company developing a new class of disease-modifying treatments for patients with axonal degeneration, including those with multiple sclerosis (MS). In its announcement, Lilly committed to advancing Disarms prospective therapies, currently in preclinical development. These programs include SARM1 for axonal degeneration the deterioration and loss of function of the axon, the long slender projections of nerve cells. Continue reading →

October 22, 2020 06:30 ET | Source: MediciNova, Inc. LA JOLLA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a multi-center, placebo-controlled, randomized Phase 2b trial to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy (CIPN). Continue reading →

NEVADA CITY, Calif. October 22, 2020 The Yuba Watershed Institute (YWI) has hired two new staff members to assist with forest stewardship planning and implementation projects in Nevada County, in partnership with the Bureau of Land Management (BLM) and with support from the Sierra Nevada Conservancy (SNC) and California Department of Forestry and Fire Protection (CAL FIRE). In March, the YWI was awarded three grants from SNCs Proposition 1/Proposition 68 Forest Health grant program. Continue reading →